Table 1 Comparison between anti-SRP IMNM overlap SS and anti-SRP IMNM patients
Items | Anti-SRP IMNM-SS (n = 6) | Anti-SRP IMNM (n = 24) | P-value |
|---|---|---|---|
Demographics | |||
Sex(Female) | 4(66.7) | 14(58.3) | 0.545 |
Age at myositis diagnosis(years) | 39.17 ± 16.216 | 46.5 ± 13.593 | 0.264 |
Disease duration (months) | 16 ± 27.67 | 14.03 ± 17.12 | 0.827 |
Clinical manifestation | |||
Upper promixal limbs(median,MRC) | 4 | 4 | 0.25 |
Upper distal limbs(median,MRC) | 4.5 | 4 | 0.3 |
Lower promixal limbs(median,MRC) | 3.5 | 4 | 0.36 |
Lower distal limbs(median,MRC) | 4 | 4 | 0.17 |
MMT | 206 ± 38.5 | 199 ± 29.4 | 0.432 |
DAS | 3.5 ± 2.4 | 4.9 ± 2.1 | 0.191 |
MYOCAT | 11.2 ± 7 | 16 ± 8.9 | 0.21 |
Dysphagia | 0 | 8(33.3) | 0.155 |
Dyspnea | 0 | 2(8.3) | > 0.9999 |
Myalgia | 2(33.3) | 12(50) | 0.657 |
Atrophy | 0 | 14(50) | 0.019 |
Rash | 1(16.6) | 2(8.3) | 0.515 |
Examination | |||
Thyroid dysfunction | 3(50) | 9(37.5) | 0.66 |
Rheumatoid factor | 0 | 2(8.3) | > 0.9999 |
ANA abnormality | 5(83.3) | 19(79.1) | 0.553 |
Lupus Anticoagulant | 0 | 2(8.3) | > 0.9999 |
Malignancy | 0 | 10(41.6) | 0.068 |
Statin exposure | 0 | 1(4.2) | > 0.9999 |
Smoking | 0 | 2(8.3) | > 0.9999 |
Drinking | 0 | 2(8.3) | > 0.9999 |
Diabete | 0 | 2(8.3) | > 0.9999 |
Hypertension | 1(16.6) | 1(4.2) | 0.366 |
CK(U/l) | 6238 ± 3443 | 3485 ± 4244 | 0.155 |
LDH(U/l) | 826 ± 524 | 639 ± 447 | 0.115 |
ESR(mm/H) | 20.5 ± 6.36 | 14.79 ± 15.39 | 0.621 |
hsCRP(mg/L) | 3.38 ± 3.8 | 16.59 ± 24.19 | 0.307 |
NI-PRO-BNP(pg/ml) | 18.67 ± 12.662 | 87.38 ± 82.442 | 0.177 |
Alb(g/L) | 38.083 ± 5.53 | 36.84 ± 5.23 | 0.616 |
Glb(g/L) | 26.72 ± 4.57 | 30.17 ± 8.05 | 0.366 |
WBC(*109/L) | 9.45 ± 4.48 | 10.23 ± 4.77 | 0.718 |
Neutrophil(*109/L) | 6.9 ± 4.5 | 7.11 ± 4.3 | 0.922 |
Lymphocyte(*109/L) | 1.76 ± 0.8 | 2.5 ± 1.09 | 0.128 |
TnI(pg/ml) | 17.8 ± 5.14 | 38.1 ± 45.481 | 0.113 |
CK-MB(ng/ml) | 562.5 ± 573.464 | 92.91 ± 83.804 | 0.453 |
Myoglobin(ng/ml) | 883.6 ± 196.28 | 401.23 ± 379.846 | 0.015 |
GLU(mmol/L) | 4.65 ± 0.354 | 6.8 ± 6.0 | 0.63 |
HbA1c(%) | 5.35 ± 0.63 | 6.2 ± 2.2 | 0.602 |
ALT (U/l) | 134.5 ± 55.2 | 83.5 ± 67.94 | 0.104 |
AST (U/l) | 457.83 ± 493.311 | 110.17 ± 98.0 | 0.145 |
Cr(umol/L) | 33.6 ± 12.3 | 42.57 ± 14.67 | 0.21 |
C4(g/L) | 0.21 ± 0.042 | 0.19 ± 0.07 | 0.909 |
C3(g/L) | 0.93 ± 0.172 | 0.93 ± 0.125 | 0.972 |
IgA(g/L) | 2.48 ± 0.752 | 1.99 ± 0.682 | 0.217 |
IgG(g/L) | 13.83 ± 0.866 | 12.78 ± 2.79 | 0.477 |
IgM(g/L) | 1.36 ± 0.646 | 1.42 ± 0.929 | 0.906 |
Interstitial lung disease | 2(33.3) | 1(4.1) | 0.23 |
Cardiac abnormality | 3(50) | 5(25.0) | 0.352 |
Ejection Fraction | 0.63 ± 0.014 | 0.68 ± 0.06 | 0.282 |
Treatment | |||
Corticosteroids monotherapy | 1(16.7) | 10(41.7) | / |
Corticosteroids plus Immunosuppressant | 5(83.3) | 14(58.3) | / |
Follow-up | |||
Follow-up period, median (range), months | 36(6–120) | 50(24–90) | 0.815 |
Lost to follow-up | 0 | 1(4.1) | > 0.9999 |
Prognosis | |||
No improvement | 0 | 0 | / |
improvement | 5(83.3) | 19(73.7) | / |
Marked improvement | 1(16.7) | 5(20.8) | / |
Relapse | 1(16.7) | 2(8.3) | / |